Mitsubishi UFJ Trust & Banking’s CytomX Therapeutics CTMX Stock Holding History

Mitsubishi UFJ Trust & Banking’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$128K	Buy	+34,191	New	+$131K	﹤0.01%	1470

Other funds holding CTMX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

Mitsubishi UFJ Trust & Banking's CTMX Position: Q2 2026 in Review

Mitsubishi UFJ Trust & Banking opened a new position in CytomX Therapeutics (CTMX) in Q2 2026: 34,191 shares worth $128K. The stake represents ﹤0.01% of the portfolio and ranks #1470 among its holdings.

44 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

Mitsubishi UFJ Trust & Banking held 34,191 shares of CytomX Therapeutics worth $128K as of Q2 2026.
CytomX Therapeutics was a new Mitsubishi UFJ Trust & Banking position in Q2 2026.
CytomX Therapeutics made up ﹤0.01% of Mitsubishi UFJ Trust & Banking's portfolio in Q2 2026, its #1470 holding.
44 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Mitsubishi UFJ Trust & Banking's 13F filing for Q2 2026, filed 6 Aug 2026.